UK shareholder meetings calendar - next 7 days
10th Jul 2026 13:43
| Price | 0.145p on 10-07-2026 at 19:07:43 |
|---|---|
| Change | -0.005p -3.33% |
| Buy | 0.15p |
| Sell | 0.14p |
| Last Trade: | Buy 500,000.00 at 0.148p |
| Day's Volume: | 127,365,635 |
| Last Close: | 0.145p |
| Open: | 0.15p |
| ISIN: | GB00BLH13C52 |
| Day's Range | 0.135p - 0.15p |
| 52wk Range: | 0.135p - 0.78p |
| Market Capitalisation: | £1.91m |
| VWAP: | 0.146361p |
| Shares in Issue: | 1.32b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
ValiRx (VAL) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 500,000 | 0.148p | Ordinary |
16:05:15 - 10-Jul-26 |
| Unknown* | 40,000,000 | 0.15p | Negotiated Trade |
15:47:47 - 10-Jul-26 |
| Unknown* | 40,000,000 | 0.1485p | Negotiated Trade |
15:47:38 - 10-Jul-26 |
| Unknown* | 5,000,000 | 0.14p | Ordinary |
13:57:27 - 10-Jul-26 |
| Buy* | 60,000 | 0.148p | Ordinary |
13:52:03 - 10-Jul-26 |
| Buy* | 35,716 | 0.148p | Ordinary |
13:46:06 - 10-Jul-26 |
| Buy* | 357,142 | 0.14p | Ordinary |
13:43:14 - 10-Jul-26 |
| Buy* | 357,142 | 0.14p | Ordinary |
13:42:36 - 10-Jul-26 |
| Buy* | 1,568 | 0.14p | Ordinary |
13:40:15 - 10-Jul-26 |
| Unknown* | 15,000,000 | 0.14p | Negotiated Trade |
13:37:48 - 10-Jul-26 |
ValiRx (VAL) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 22nd Jun 2026 7:00 am | RNS | Conclusion of Evaluation with University of Dundee |
| 22nd Jun 2026 7:00 am | RNS | Final Results & Notice of AGM |
| 2nd Jun 2026 7:00 am | RNS | Conclusion of Evaluation with Stingray |
| 1st Jun 2026 7:00 am | RNS | ValiRx Exercises Option on Evaluation Asset |
| 27th May 2026 7:00 am | RNS | Cytolytix Patent Granted |
| 21st May 2026 7:00 am | RNS | Result of Oversubscribed WRAP Retail Offer |
| 18th May 2026 7:00 am | RNS | WRAP Retail Offer for up to £150,000 |
| 15th May 2026 7:00 am | RNS | Fundraising of up to £1,155,000 |
| 31st Mar 2026 10:15 am | RNS | Change of Registered Office |
| 26th Mar 2026 7:00 am | RNS | ValiRx Commercial Update Q1 2026 |